Multiple vaccine candidates based on RNA and DNA technologies, inactivated viruses, and other approaches have been rapidly developed to combat the coronavirus disease 2019 (COVID-19) pandemic.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of COVID-19, poses a severe threat to global health and has already claimed millions of lives worldwide. Two messenger ribonucleic acid (mRNA) vaccines, namely the BNT162b2 (Pfizer/BioNTech) and the mRNA-1273 (Moderna) vaccines, have received significant attention and are being widely deployed in many countries.
